Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate
Bibliographic record
Abstract
Introduction: Tenofovir disoproxil fumarate (TDF) is active against lamivudine resistant hepatitis B virus (HBV). Response to TDF treatment in a subset of patients from the phase 3, studies 102 (HBeAg-negative patients) and 103 (HBeAg-positive patients) previously treated for >12 weeks with lamivudine or emtricitabine (LAM-experienced) was compared to LAM-naïve patients in these two studies. Goal: To determine if the safety and efficacy of TDF treatment is comparable at week (W) 96 in LAM-experienced and LAM-naïve patients. Methods: In studies 102 and 103, CHB patients were randomized 2:1 to double-blind, once daily TDF 300mg or adefovir dipivoxil (ADV) 10mg. At W48, patients with a W48 biopsy initiated open-label TDF for up to 7 additional years. A total of 426 patients were initially randomized to TDF (51 LAM-experienced and 375 LAM-naïve). The majority of LAM-experienced patients were HBeAg-negative (N=41). Results: Forty-seven LAM-experienced patients and 350 LAM-naïve patients completed 96 weeks (2 years) of TDF treatment. Baseline demographics and disease characteristics of LAM-experienced patients included a mean age of 45 years, 78% Caucasian, 71% male and mean HBV DNA of 7.2 log 10 copies/mL. A similar proportion of patients achieved viral suppression (HBV DNA <400 c/mL; 69 IU/mL) at week 96 in the LAM-experienced versus LAM-naïve subgroup: 92% versus 84% (ITT) and 98% versus 95% (on-treatment). Mean ALT at W96 in LAM-experienced and LAM-naïve patients was 31.7 U/L and 35.5 U/L, respectively. No LAM-experienced patient achieved HBsAg loss. No HBV pol/RT amino acid substitutions associated with TDF resistance were detected through 96 weeks of TDF monotherapy in LAM-experienced patients. Cumulatively over 2 years, 2 LAM-experienced patients had serious AEs considered related to TDF (ALT flares) and no LAM-experienced patient discontinued due to an AE. No LAM-experienced patient had a confirmed decrease in creatinine clearance <50 mL/min or confirmed increase in creatinine of ≥0.5mg/dL. Conclusion: The safety, efficacy and resistance surveillance results for 96 weeks of TDF treatment were similar in LAM-experienced and LAM-naïve CHB patients. Longer follow up is ongoing.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".